Publications
Publications Highlight
Aims for the study: To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting...
Aims for the study: To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting...
Retrospective cross sectional evaluation of the LIVERFASt Test for staging liver fibrosis in MASLD patients in NIDDK studies’ populations using liver biopsy
MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis
Application of LIVERFASt Biomarkers to Evaluate Longitudinal Hepatic Fibrosis and Inflammation after HCV cure
Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma. Successful Direct
Comparison of the prevalence of advanced fibrosis (AF) using two combinations: Liver stiffness measurement (LSM or VCTE Fibroscan) along with LIVERSTAT (LST) or FIB-4 in a prospective chronic liver diseases (CLD) cohort
AI-based blood tests LIVERSTAT for advanced fibrosis (AF) in patients with T2D can streamline the diagnostic process. Aim
MASLD affects more than 25% of subjects of the general population and can progress to advanced fibrosis...
Hepatitis C virus (HCV) infection is a common cause of both liver cirrhosis and hepatocellular carcinoma....
AI-based blood tests LIVERSTAT for advanced fibrosis (AF) in patients with T2D can streamline the diagnostic...
